JP2014520787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520787A5
JP2014520787A5 JP2014517822A JP2014517822A JP2014520787A5 JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122427B2 (ja
JP2014520787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063249 external-priority patent/WO2013004818A1/en
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067.7 2011-07-07
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 true JP2014520787A5 (OSRAM) 2015-08-13
JP6122427B2 JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (OSRAM)
EP (1) EP2729130B1 (OSRAM)
JP (1) JP6122427B2 (OSRAM)
KR (1) KR102058097B1 (OSRAM)
CN (1) CN103826616B (OSRAM)
AU (1) AU2012280198B2 (OSRAM)
BR (1) BR112014000290B1 (OSRAM)
CA (1) CA2838659C (OSRAM)
CY (1) CY1121999T1 (OSRAM)
DK (1) DK2729130T3 (OSRAM)
EA (1) EA026587B1 (OSRAM)
ES (1) ES2651212T3 (OSRAM)
HR (1) HRP20171889T1 (OSRAM)
HU (1) HUE035241T2 (OSRAM)
IL (1) IL229933A (OSRAM)
LT (1) LT2729130T (OSRAM)
MX (1) MX343689B (OSRAM)
NO (1) NO2729130T3 (OSRAM)
PL (1) PL2729130T3 (OSRAM)
PT (1) PT2729130T (OSRAM)
RS (1) RS56667B1 (OSRAM)
SI (1) SI2729130T1 (OSRAM)
SM (1) SMT201700574T1 (OSRAM)
WO (1) WO2013004818A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
JP2015508822A (ja) * 2012-03-01 2015-03-23 ギリアード サイエンシーズ, インコーポレイテッド 噴霧乾燥製剤
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
WO2018029566A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A high drug loaded tablet composition for treating hiv
US20190175511A1 (en) * 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
EP3496718A4 (en) 2016-08-08 2020-01-22 Hetero Labs Limited ANTIRETROVIRAL COMPOSITIONS
WO2018064071A1 (en) * 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EP3654951A1 (en) 2017-07-20 2020-05-27 Janssen Sciences Ireland Unlimited Company Compositions comprising darunavir, cobicistat, emtricitabine and tenofovir alafenamide for use in the treatment of hiv
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ATE500823T1 (de) 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Arzneimittel zur behandlung von hiv-infizierten säugetieren
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
HRP20041061B1 (hr) 2002-05-16 2015-02-27 Tibotec Pharmaceuticals Ltd. Pseudopolimorfni oblici inhibitora hiv proteaze
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
BRPI0718428A2 (pt) * 2006-10-25 2013-11-12 Mcneil Ppc Inc Composição de ibuprofeno
EP2118082B1 (en) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2689330A1 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Combination formulations
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
KR101546712B1 (ko) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. 히스타민 h3 수용체의 조절제로서 사이클로알킬옥시- 및 헤테로사이클로알킬옥시피리딘 화합물
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
AP3089A (en) * 2008-05-02 2015-01-31 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
BRPI1008664A2 (pt) * 2009-02-06 2016-03-08 Gilead Sciences Inc comprimidos para a terapia de combinação
EP2477992B1 (en) * 2009-09-17 2016-12-14 Mylan Laboratories Limited Processes for the preparation of darunavir and the amorphous form thereof
US20130195978A1 (en) 2010-05-10 2013-08-01 Hetero Research Foundation Darunavir Compositions
ES2598823T3 (es) 2011-07-07 2017-01-30 Janssen R&D Ireland Formulaciones de darunavir
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
EP3240793A1 (en) 2015-01-03 2017-11-08 Mylan Laboratories Ltd. Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2011093937A5 (OSRAM)
JP2013539946A5 (OSRAM)
JP2013531034A5 (OSRAM)
JP2013531018A5 (OSRAM)
JP2014503786A5 (OSRAM)
JP2012023335A5 (OSRAM)
JP2014026276A5 (OSRAM)
JP2014026274A5 (OSRAM)
JP2014026275A5 (OSRAM)
JP2014505137A5 (OSRAM)
JP2015500269A5 (OSRAM)
JP2012204203A5 (OSRAM)
JP2013064178A5 (OSRAM)
JP2014189812A5 (OSRAM)
JP2014520787A5 (OSRAM)
JP2015107586A5 (OSRAM)
JP2012193264A5 (OSRAM)
JP2012190699A5 (OSRAM)
JP2014531903A5 (OSRAM)
JP2011233516A5 (OSRAM)
JP2014534151A5 (OSRAM)
JP2014520786A5 (OSRAM)
JP2014005521A5 (OSRAM)
JP2013016377A5 (OSRAM)
JP2015127764A5 (OSRAM)